PEPTIDE GUIDE

Is Tirzepatide a Peptide?

Yes. Tirzepatide is a synthetic peptide made from a chain of 39 amino acids. It was designed in a laboratory, but its structure is based mainly on glucose-dependent insulinotropic polypeptide, usually shortened to GIP. It has also been engineered to activate the receptor for glucagon-like peptide 1, better known as GLP-1.

Tirzepatide is the active ingredient in Mounjaro and Zepbound. These are approved prescription medicines with different labelled uses. Mounjaro is used for type 2 diabetes and to reduce major cardiovascular events in defined adults with type 2 diabetes. Zepbound is used for long-term weight management in defined adults and for moderate to severe obstructive sleep apnoea in adults with obesity.

The molecule has been studied in large human programmes covering diabetes, obesity, cardiovascular outcomes, sleep apnoea, heart failure and liver disease. Some of those findings support approved uses. Others remain research findings and should not be presented as approved treatment claims.

Research statusApproved medicine with extensive human evidence
Peptide typeDual GIP and GLP-1 analogue
Peptide length39 amino acids
Receptor targetsGIP + GLP-1
Last reviewed17 November 2026
THE SHORT ANSWER

Tirzepatide is a modified 39-amino-acid peptide. It is based mainly on the natural GIP hormone and designed to activate both GIP and GLP-1 receptors.

It is not insulin, a steroid or the same molecule as semaglutide. It is used in approved medicines, but approval belongs to the finished Mounjaro and Zepbound products and their defined uses. It does not extend automatically to every product carrying the tirzepatide name.

IDENTITY

What makes tirzepatide a peptide?

A peptide is a chain of amino acids connected by peptide bonds. Tirzepatide fits that description directly. Its backbone contains 39 amino-acid residues arranged in a defined sequence.

If you want the foundation first, Orentra's guide to what peptides are explains how amino-acid chains act as hormones, signals and medicines.

Tirzepatide is synthetic, but synthetic and peptide are not opposing categories. Synthetic explains how the molecule is made. Peptide describes its molecular structure. A peptide can occur naturally, copy a natural sequence or be deliberately redesigned.

Tirzepatide belongs to the third group. Its sequence was designed from a natural hormone template, then modified to change its receptor activity, resistance to breakdown and time in circulation. Scientific papers first described the development compound as LY3298176 before the medicine received the name tirzepatide.

Calling tirzepatide a peptide tells you what kind of molecule it is. It does not tell you whether a specific vial or finished product is approved, correctly manufactured or suitable for a person. Those questions need product-level evidence.

TypeModified synthetic peptide
Length39 amino acids
Sequence basisHuman GIP
TargetsGIP + GLP-1 receptors
STRUCTURE

What is tirzepatide made from?

Most of tirzepatide's sequence is based on human GIP, one of the incretin hormones released by the gut after food is eaten. Its 39-amino-acid backbone carries the biological message, while several deliberate changes alter how that message behaves.

Two positions contain aminoisobutyric acid, usually shortened to Aib. Aib is not one of the standard amino acids directly encoded into human proteins. These substitutions help protect the peptide against rapid enzymatic breakdown.

Another position carries a fatty diacid side chain attached through a chemical linker. The side chain helps tirzepatide bind to albumin, a common protein in the blood. Albumin binding slows clearance and helps the molecule remain available for much longer than natural GIP or GLP-1.

The peptide also has a modified end group. Taken together, the sequence, substitutions, linker and fatty side chain form one defined molecule. Tirzepatide is not a loose mixture of GIP and GLP-1.

Current prescribing information reports an approximate half-life of five days. Half-life is the time needed for the amount of a substance in the body to fall by half. It describes persistence in the body, not the time for every trace to disappear.

Structural featureWhat it means
39-amino-acid backboneThe chain that makes tirzepatide a peptide
Sequence based mainly on GIPA natural incretin hormone provided the main design template
Two Aib residuesSelected positions help resist rapid enzymatic breakdown
Fatty diacid side chainSupports albumin binding and slower clearance
Modified end groupA chemical change at the end of the peptide chain
DEVELOPMENT

How was tirzepatide developed?

Tirzepatide grew out of research into incretin hormones. Incretins are gut signals that help coordinate the body's response to food. GLP-1 medicines had already shown that a natural peptide pathway could be turned into useful diabetes treatment. Researchers then explored whether one molecule could activate both GIP and GLP-1 receptors.

The early compound LY3298176 was designed as a fatty-acid-modified peptide with activity at both receptors. Laboratory studies measured receptor binding, signalling, glucose effects and body-weight changes before the molecule moved into human trials.

An early randomised phase 2 trial compared several tirzepatide treatment levels with placebo and dulaglutide in adults with type 2 diabetes. It found larger average improvements in long-term blood-glucose measures and body weight at several tirzepatide levels, while gastrointestinal adverse effects became more common as exposure increased.

Phase 3 development then separated the main questions. SURPASS studied type 2 diabetes. SURMOUNT studied obesity and related conditions. Later trials examined cardiovascular outcomes, obstructive sleep apnoea, heart failure and MASH. Each programme answers a different clinical question.

The development history also shows why an active molecule is only one part of a medicine. Regulators assess the finished formulation, manufacturing, clinical evidence, device, labelling and safety controls together.

MECHANISM

How does tirzepatide work?

Tirzepatide binds to and activates two receptor systems: the GIP receptor and the GLP-1 receptor. Both belong to the incretin system, but they are not identical receptors and do not produce identical signals.

Its main measured effects include:

  • Increasing insulin when blood glucose is elevated. This helps the body move glucose out of the bloodstream after food.
  • Reducing glucagon. Glucagon can tell the liver to release glucose. Lowering an inappropriately high signal can improve glucose control.
  • Reducing appetite and food intake. Incretin signalling reaches brain systems involved in hunger, fullness and eating behaviour.
  • Delaying stomach emptying. Food and oral medicines may leave the stomach more slowly, especially early in treatment.
  • Changing metabolic measures through weight loss and glucose control. Blood pressure, blood fats, liver fat and other markers can change as part of the wider response.

These effects overlap. Weight loss is not explained by stomach emptying alone, and glucose control is not simply a result of eating less. Tirzepatide affects several linked pathways at the same time.

Mechanistic studies describe tirzepatide as imbalanced and biased. In plain English, it does not activate both receptors in exactly the same way or strength as the natural hormones. Receptor signalling is more complicated than adding one full GIP effect to one full GLP-1 effect.

Human trials establish what the complete medicine does in people. Laboratory receptor results help explain those findings, but they cannot replace clinical evidence.

INCRETIN BIOLOGY

What is GIP?

GIP stands for glucose-dependent insulinotropic polypeptide. Older sources sometimes call it gastric inhibitory polypeptide. It is a peptide hormone released from the gut after food is eaten.

One of GIP's best-known roles is helping the pancreas release insulin when glucose is present. The glucose-dependent part of the name is useful. The insulin signal becomes more relevant when blood glucose is raised rather than acting as a fixed command at every glucose level.

GIP receptors are found in several tissues. Research into GIP covers pancreatic cells, fat tissue, bone, the nervous system and other metabolic pathways. Not every laboratory effect has the same clinical importance, and the full contribution of GIP receptor activity to tirzepatide's results is still being studied.

Tirzepatide is based mainly on the GIP sequence, but it is not natural GIP. The engineered molecule lasts much longer and also activates the GLP-1 receptor.

INCRETIN BIOLOGY

What is GLP-1?

GLP-1 stands for glucagon-like peptide 1. It is another natural peptide hormone released from the gut after eating.

GLP-1 receptor activity can increase glucose-dependent insulin release, lower glucagon, delay stomach emptying and affect appetite. Natural GLP-1 is broken down quickly, so medicinal peptides acting on the receptor are modified to remain active for longer.

Tirzepatide is often grouped with GLP-1 medicines because it activates the GLP-1 receptor and shares several clinical effects with that class. The shorthand leaves out its GIP receptor activity. Dual GIP and GLP-1 receptor agonist is the fuller description.

GLP-1 is a hormone and a receptor pathway, not a brand name. Tirzepatide, semaglutide and natural GLP-1 are separate molecules even though they overlap in receptor biology.

COMPARISON

How is tirzepatide different from natural GIP and GLP-1?

Natural GIP and GLP-1 are short-lived hormones made by the body. They rise in response to food and are then broken down quickly. Tirzepatide is a manufactured peptide designed to reproduce selected parts of both signalling systems while remaining active for much longer.

FeatureNatural GIPNatural GLP-1Tirzepatide
Molecule typePeptide hormonePeptide hormoneModified synthetic peptide
Main receptorGIP receptorGLP-1 receptorGIP and GLP-1 receptors
SourceProduced in the bodyProduced in the bodyManufactured as a defined drug substance
Time in circulationShortShortExtended through structural modification
Clinical statusNatural hormoneNatural hormoneActive ingredient in approved medicines

Tirzepatide is one peptide with one defined sequence. It should not be described as natural GIP and GLP-1 mixed together. Its activity comes from the way the engineered molecule interacts with both receptors.

APPROVED USES

What is tirzepatide used for?

The answer depends on the finished medicine. In the United States, Mounjaro and Zepbound contain the same active molecule but have different approved uses.

Mounjaro

Mounjaro is approved alongside diet and exercise to improve blood-glucose control in adults and children aged 10 years and older with type 2 diabetes.

The August 2026 US label also includes reducing major cardiovascular events in adults with type 2 diabetes who are at high risk. These events are cardiovascular death, non-fatal heart attack or non-fatal stroke. This is a defined cardiovascular indication, not a general weight-management approval.

Zepbound

Zepbound is approved to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight who also have at least one weight-related medical condition. The approval sits alongside reduced-calorie diet and increased physical activity.

Zepbound is also approved to treat moderate to severe obstructive sleep apnoea in adults with obesity. The indication came from two dedicated sleep-apnoea trials rather than being inferred from weight loss alone.

Zepbound's effectiveness has not been established in children under its current US label. Mounjaro's paediatric diabetes indication should not be transferred to Zepbound.

PRODUCT NAMES

Is tirzepatide the same as Mounjaro or Zepbound?

Tirzepatide is the active molecule. Mounjaro and Zepbound are finished prescription medicines containing it.

NameWhat it meansCurrent US approval
TirzepatideThe active 39-amino-acid peptideNot a complete product name by itself
MounjaroAn approved tirzepatide medicineType 2 diabetes in defined adult and paediatric patients; cardiovascular risk reduction in defined adults with type 2 diabetes
ZepboundAn approved tirzepatide medicineWeight management and obstructive sleep apnoea in defined adults

The brands are not interchangeable labels for every item containing tirzepatide. Approval covers the complete medicine, including its formulation, manufacturing process, product presentation, stability, labelling and intended use.

Clinical evidence should remain attached to the product and population studied. A Mounjaro diabetes result does not automatically add a diabetes indication to Zepbound, and a Zepbound weight-management result does not turn an unrelated tirzepatide vial into Zepbound.

CLASSIFICATION

Is tirzepatide insulin?

No. Tirzepatide is not insulin.

Insulin is a hormone that directly helps cells take up glucose. Tirzepatide activates GIP and GLP-1 receptors and can encourage the pancreas to release more insulin when blood glucose is elevated. It also affects glucagon, appetite, food intake and stomach emptying.

Tirzepatide does not replace insulin in every person who needs insulin. Some diabetes trials studied it alongside insulin, while others compared it with insulin. Those are treatment questions for a prescriber, not evidence that one medicine can be substituted without clinical review.

The risk of low blood glucose is generally greater when tirzepatide is combined with insulin or medicines that increase insulin release. This is one reason the complete medicine list matters.

CLASSIFICATION

Is tirzepatide a steroid?

No. Tirzepatide is a peptide, not a steroid.

Steroids have a characteristic ring-based chemical structure and act through steroid hormone receptors. Tirzepatide is an amino-acid chain that acts at GIP and GLP-1 receptors. It is also not testosterone, a stimulant, a fat burner or a bodybuilding treatment.

HUMAN EVIDENCE

What does the human evidence show?

Tirzepatide has extensive human evidence. Its approved uses are supported by randomised controlled trials and regulatory review, while additional trials have investigated outcomes beyond the current labels.

The evidence needs to be read by question. SURPASS focused mainly on type 2 diabetes. SURMOUNT focused on obesity and related conditions. SURPASS-CVOT measured major cardiovascular events. SURMOUNT-OSA measured sleep-apnoea outcomes. SUMMIT studied people with obesity-related heart failure with preserved ejection fraction. SYNERGY-NASH studied liver histology in MASH.

An improvement in blood glucose, body weight or a scan is not automatically the same as fewer clinical events. A trial can provide good evidence for one outcome while leaving another unanswered. Approval can also remain narrower than the complete research programme.

Trial averages cannot predict what one person will experience. Some participants responded more strongly, some less strongly, and some stopped treatment because of adverse effects or other reasons.

See how Orentra evaluates research →
TYPE 2 DIABETES

What does the diabetes evidence show?

The SURPASS programme studied tirzepatide across several type 2 diabetes settings. Some participants were managing diabetes without other glucose-lowering medicines at enrolment. Others were taking metformin, additional tablets or insulin. This range helps show that the effect is not limited to one narrow treatment situation.

SURPASS-1 compared tirzepatide with placebo in adults whose diabetes was not adequately controlled with diet and exercise alone. At 40 weeks, average HbA1c fell by about 1.9 to 2.1 percentage points across the tirzepatide groups, while it rose slightly with placebo. HbA1c is a measure of average blood glucose over the previous two to three months. Body weight also fell in the tirzepatide groups.

SURPASS-2 directly compared tirzepatide with injectable semaglutide in adults taking metformin. Tirzepatide produced larger average reductions in HbA1c and body weight at each treatment level studied. The trial supports a head-to-head conclusion for that population, comparator and study period. It does not prove that tirzepatide is better for every person, outcome or semaglutide product.

SURPASS-3 and SURPASS-4 compared tirzepatide with long-acting insulins. Average HbA1c and body-weight changes favoured tirzepatide, while the insulin groups gained weight on average. Low blood glucose was less frequent with tirzepatide in these comparisons, though treatment context and background medicines still affect the risk.

SURPASS-5 added tirzepatide or placebo to insulin glargine. HbA1c improved more with tirzepatide, but gastrointestinal adverse effects were also more common. The trial shows that tirzepatide can be studied alongside insulin without implying that patients should create their own combination or alter insulin treatment without a prescriber.

The current Mounjaro label also includes a paediatric trial in people aged 10 years and older with type 2 diabetes. This evidence supports the paediatric Mounjaro indication. It does not establish Zepbound use in children.

These trials support improved glucose control. They do not mean tirzepatide cures type 2 diabetes. Long-term management depends on the person, ongoing treatment, other medicines and wider care.

Participants underwent protocol-controlled escalation where the study required it. The table reports the treatment levels compared in each trial without reproducing the escalation schedules.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
SURPASS-1Subcutaneous tirzepatide 5 mg, 10 mg or 15 mg once weeklyPlacebo40 weeks
SURPASS-2Subcutaneous tirzepatide 5 mg, 10 mg or 15 mg once weeklySubcutaneous semaglutide 1 mg once weekly40 weeks
SURPASS-3Subcutaneous tirzepatide 5 mg, 10 mg or 15 mg once weeklySubcutaneous insulin degludec once daily, titrated under the protocol52 weeks
SURPASS-4Subcutaneous tirzepatide 5 mg, 10 mg or 15 mg once weeklySubcutaneous insulin glargine once daily, titrated under the protocolPrimary assessment at 52 weeks
SURPASS-5Subcutaneous tirzepatide 5 mg, 10 mg or 15 mg once weekly, added to insulin glarginePlacebo added to insulin glargine40 weeks
WEIGHT MANAGEMENT

What does the weight-management evidence show?

The SURMOUNT trials studied tirzepatide for weight management in different groups and under different study designs.

SURMOUNT-1 enrolled 2,539 adults with obesity or overweight and at least one weight-related condition, excluding diabetes. Everyone received lifestyle support. After 72 weeks, mean body-weight reductions across the tirzepatide groups ranged from 15.0% to 20.9%, compared with 3.1% with placebo. Half or more of the participants in the two higher-exposure groups lost at least 20% of their starting weight.

These are treatment-group averages. They are not a promise of a particular result. Participants had varied responses, and adverse effects led some people to stop treatment.

SURMOUNT-2 studied adults with obesity or overweight and type 2 diabetes. Average weight loss was smaller than in SURMOUNT-1, which excluded diabetes, but remained substantially greater with tirzepatide than with placebo. The difference is a useful warning against moving a headline result from one population into another.

SURMOUNT-3 began with an intensive lifestyle programme. Only participants who first lost at least 5% of their starting weight entered the randomised phase. Tirzepatide produced further average weight loss, while the placebo group regained some weight. The result shows that medication and structured lifestyle treatment were studied together, not as opposing choices.

SURMOUNT-4 used a withdrawal design. Everyone first received tirzepatide. Those who then continued treatment lost more weight on average, while those who changed to placebo regained weight. This addresses maintenance rather than initial response.

Longer follow-up from SURMOUNT-1 examined participants with obesity and prediabetes. Over three years, sustained weight reduction was accompanied by fewer cases progressing to type 2 diabetes during the treatment period. This is important evidence, but it does not turn Zepbound into an approved medicine for diabetes prevention. The label still defines the approved uses.

Participants underwent protocol-controlled escalation where the study required it. The table reports the treatment levels used for comparison without reproducing the escalation schedules.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
SURMOUNT-1Subcutaneous tirzepatide 5 mg, 10 mg or 15 mg once weeklyPlacebo72 weeks
SURMOUNT-2Subcutaneous tirzepatide 10 mg or 15 mg once weeklyPlacebo72 weeks
SURMOUNT-3Subcutaneous tirzepatide 10 mg or 15 mg once weekly, according to the maximum tolerated level in the protocolPlacebo12-week lifestyle lead-in, then 72-week randomised period
SURMOUNT-4Subcutaneous tirzepatide 10 mg or 15 mg once weekly, according to the maximum tolerated level in the protocolContinuation or change to placebo36-week tirzepatide lead-in, then 52-week randomised period
AFTER TREATMENT

What happens after tirzepatide is stopped?

SURMOUNT-4 provides the clearest controlled evidence. After an initial treatment period, participants were randomly assigned either to continue tirzepatide or change to placebo.

From that point to the end of the study, people who continued treatment lost a further 5.5% of body weight on average. People who changed to placebo regained 14.0% on average. Measured from the original start of the study, both groups still remained below their starting weight, but the difference between continued treatment and withdrawal was large.

This does not mean every person regains the same amount or that treatment should never stop. It shows that the biological pressures influencing appetite and body weight can continue. Results measured during treatment should not be described as a permanent reset after treatment ends.

The trial also does not provide a stopping plan for an individual. Decisions about continuing, changing or stopping a prescribed medicine require the prescriber to consider benefits, adverse effects, other conditions and the person's preferences.

SourcesJAMA, 2024
ADOLESCENT RESEARCH

What did the SURMOUNT-ADOLESCENTS trial find?

SURMOUNT-ADOLESCENTS was a Phase 3 trial published in JAMA on 15 November 2026. It randomly assigned 160 adolescents aged 12 to 17 with obesity, or overweight and a related health complication, to tirzepatide or placebo alongside lifestyle support. Participants and researchers did not know which treatment each person received during the 72-week study.

Body mass index (BMI), a measure of weight relative to height, fell by an average of 18.5% with tirzepatide and rose by 0.5% with placebo in the main treatment-regimen analysis. That analysis includes the effects of stopping treatment and other events specified in the protocol. A separate analysis estimating results under continued treatment reported a larger BMI reduction, but the two analyses answer different questions and should not be mixed.

Gastrointestinal effects, including nausea, vomiting and diarrhoea, were the most frequent adverse events. Longer-term effects on growth and development remain uncertain. Most participants were already in later puberty, and very few had type 2 diabetes, so the findings cannot be assumed to apply equally to younger adolescents or those with diabetes. A published trial result does not itself grant a new regulatory approval for an age group.

SourcesJAMA, 2026
SLEEP APNOEA

What does the obstructive sleep apnoea evidence show?

Obstructive sleep apnoea happens when the upper airway repeatedly narrows or closes during sleep. Breathing can pause, blood oxygen can fall and sleep becomes fragmented. Obesity is an important risk factor, but it is not the only cause.

SURMOUNT-OSA included two randomised trials in adults with moderate to severe obstructive sleep apnoea and obesity who did not have type 2 diabetes. One trial enrolled people who were unable or unwilling to use positive airway pressure. The other enrolled people who were already using it.

The main outcome was change in the apnoea-hypopnoea index, which counts breathing interruptions per hour of sleep. At 52 weeks, the index fell substantially more with tirzepatide than with placebo in both trials. Tirzepatide also reduced body weight, hypoxic burden and several cardiovascular-risk measures.

These findings supported the Zepbound indication for moderate to severe obstructive sleep apnoea in adults with obesity. The approval is not a general claim that tirzepatide treats snoring, central sleep apnoea or sleep apnoea in people outside the defined group.

Positive airway pressure remains an important treatment. The trial including people using it did not establish that everyone can replace a prescribed device with medication. Sleep-apnoea treatment should be reviewed with a clinician who can assess symptoms, sleep testing and wider risk.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
SURMOUNT-OSASubcutaneous tirzepatide 10 mg or 15 mg once weekly, according to the maximum tolerated level in the protocolPlacebo52 weeks
CARDIOVASCULAR OUTCOMES

What does the cardiovascular evidence show?

Blood glucose, body weight, blood pressure and blood fats can all affect cardiovascular risk. Improvements in those measures are encouraging, but they do not replace a trial that counts heart attacks, strokes and cardiovascular deaths.

SURPASS-CVOT was designed for that question. It enrolled 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Tirzepatide was compared with dulaglutide, an established GLP-1 receptor agonist with cardiovascular evidence, rather than with placebo.

The primary outcome combined cardiovascular death, heart attack and stroke. Over a median follow-up of about four years, the event rate was 12.2% with tirzepatide and 13.1% with dulaglutide. Tirzepatide met the trial's non-inferiority requirement. The hazard ratio was 0.92, with a 95.3% confidence interval from 0.83 to 1.01. A hazard ratio of 1 means no difference in event rates over time. Because the interval included 1, the trial did not establish superiority. Non-inferiority means it excluded being worse than the comparison medicine by more than a margin defined before analysis.

The trial did not establish superiority for the primary cardiovascular outcome. The estimated relative difference favoured tirzepatide, but the confidence interval crossed the point at which there would be no difference. Noninferior should not be rewritten as proven better.

Several secondary and exploratory findings favoured tirzepatide, including lower all-cause mortality, but secondary findings need to be read in the context of the complete statistical plan. Mounjaro now has a US indication for reducing major cardiovascular events in adults with type 2 diabetes who are at high risk. Zepbound should not inherit that indication. The trial comparison and the approved label describe related but distinct questions.

This differs from the SELECT evidence for semaglutide, which compared treatment with placebo in people with established cardiovascular disease and obesity or overweight without diabetes. The two trials asked different questions and should not be reduced to a simple winner.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
SURPASS-CVOTSubcutaneous tirzepatide once weekly, up to 15 mg according to the maximum tolerated level in the protocolDulaglutide 1.5 mg once weeklyMedian follow-up about four years
HEART FAILURE

What does the heart-failure evidence show?

Heart failure with preserved ejection fraction is a condition in which the heart can still squeeze out a normal proportion of blood but does not fill or function normally. Obesity can contribute through inflammation, excess blood volume, pressure on the heart and fat around the heart.

The SUMMIT trial enrolled 731 people with obesity and heart failure with preserved ejection fraction. Participants received tirzepatide or placebo in addition to their usual care.

The combined outcome of cardiovascular death or worsening heart failure occurred in 9.9% of the tirzepatide group and 15.3% of the placebo group. The difference was driven mainly by fewer worsening heart-failure events. Health-status scores also improved more with tirzepatide.

Cardiovascular deaths were uncommon and numerically higher in the tirzepatide group, but the trial was not large enough to estimate the effect on cardiovascular death alone precisely. The confidence interval was wide. The combined outcome should not be shortened to a claim that tirzepatide reduced cardiovascular death.

SUMMIT is important human evidence, but heart failure is not a current US indication in the Mounjaro or Zepbound labels. A positive trial and an approved treatment claim are separate stages.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
SUMMITSubcutaneous tirzepatide once weekly, up to 15 mg according to the maximum tolerated level in the protocolPlacebo52-week health-status assessment; median event follow-up 104 weeks
KIDNEY EVIDENCE

What does the kidney evidence show?

Kidney evidence for tirzepatide is encouraging but less direct than the dedicated FLOW kidney-outcomes trial for semaglutide.

A post hoc analysis of SURPASS-4 examined estimated kidney function, urine albumin and a composite kidney outcome in adults with type 2 diabetes and increased cardiovascular risk. Estimated kidney function declined more slowly with tirzepatide than with insulin glargine, urine albumin improved, and the composite kidney outcome occurred less often.

Post hoc means the analysis was performed using data from a trial whose main purpose was different. It can identify a useful signal, but it carries more uncertainty than a dedicated trial designed around kidney events.

More recent analyses from SURPASS-CVOT have also reported favourable kidney findings compared with dulaglutide. These results strengthen the evidence but do not currently create a general Mounjaro or Zepbound indication for chronic kidney disease.

Kidney safety also has two sides. Longer-term disease markers may improve in some studied groups, while severe vomiting or diarrhoea can cause dehydration and acute kidney injury. Benefit in one setting does not remove short-term safety risks in another.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
SURPASS-4 kidney post hoc analysisSubcutaneous tirzepatide 5 mg, 10 mg or 15 mg once weeklySubcutaneous insulin glargine once daily, titrated under the protocolPrimary trial assessment at 52 weeks
LIVER EVIDENCE

What does the MASH evidence show?

MASH stands for metabolic dysfunction-associated steatohepatitis. It was previously called NASH. It is a form of liver disease in which fat accumulation is accompanied by inflammation and liver-cell injury. Fibrosis means scar tissue has formed.

SYNERGY-NASH was a phase 2 trial in 190 adults with biopsy-confirmed MASH and moderate or severe fibrosis. After 52 weeks, MASH resolved without worsening fibrosis in 44% to 62% of participants across the tirzepatide groups, compared with 10% in the placebo group.

Improvement of at least one fibrosis stage without worsening MASH occurred in about half of the tirzepatide groups and 30% of the placebo group. The trial was promising, but it was relatively small and designed to select a treatment level and estimate biological effect rather than establish every long-term clinical outcome.

Larger and longer trials are needed to determine effects on progression to cirrhosis, liver failure, transplantation and death. Changes in biopsy findings are important, but they are not the same as directly measuring those clinical events.

Tirzepatide is not currently approved in the United States to treat MASH. The phase 2 result should not be copied into the Mounjaro or Zepbound indications.

STUDY DESIGN, NOT DOSING GUIDANCE

These are the treatment levels used in controlled clinical trials. They are included to explain how the evidence was produced. They are not dosage recommendations, prescribing instructions or guidance for personal use.

StudyTreatment level usedComparatorDuration
SYNERGY-NASHSubcutaneous tirzepatide 5 mg, 10 mg or 15 mg once weeklyPlacebo52 weeks
EVIDENCE QUALITY

How strong is the evidence?

Evidence for the approved Mounjaro and Zepbound uses is strong by the standards applied to medicines. Tirzepatide has randomised controlled trials, active-comparator trials, a large cardiovascular outcomes trial, regulatory review and post-marketing safety monitoring.

The evidence still has limits:

  • Trial results are group averages and do not predict an individual response.
  • Most major trials were funded by the manufacturer. Randomisation, control groups and publication reduce some forms of bias, but funding remains relevant.
  • Several promising conditions, including MASH and heart failure, sit outside the current US labels.
  • Kidney findings have largely come from secondary or post hoc analyses rather than a dedicated kidney-outcomes trial.
  • Long-term cardiovascular evidence now covers about four years, but lifetime outcomes remain unknown.
  • Rare harms may not become clear until much larger numbers of people have been exposed.
  • Withdrawal evidence shows that weight outcomes during treatment may not remain after treatment ends.
  • Approved-product evidence does not validate compounded or research-labelled material.

A comprehensive page does not need to treat every result as equally established. Its job is to show which questions have strong answers, which remain open and where regulatory approval stops.

SAFETY

Is tirzepatide safe?

Tirzepatide has been tested in large clinical programmes, but approved does not mean risk-free. Safety depends on the product, the person, existing conditions and other medicines.

November 2026 FDA warning about a rare eye condition

On 9 November 2026, the US Food and Drug Administration (FDA) required a warning for glucagon-like peptide-1 (GLP-1) receptor agonist medicines about a possible increased risk of non-arteritic anterior ischaemic optic neuropathy (NAION). This rare condition occurs when blood flow to part of the optic nerve is reduced. It can cause sudden, painless loss of vision in one eye, sometimes permanently.

Across 126 randomised trials involving several GLP-1 medicines, the FDA estimated 6.4 probable cases per 100,000 person-years of exposure among people receiving GLP-1 medicines, compared with 3.8 among those receiving other treatment or placebo. A person-year means one person followed for one year. These are pooled class-level figures, not a measured risk specific to this medicine. Only 15 probable events were identified in total, so the estimate is uncertain. The FDA did not identify a mechanism in the animal evidence, and the warning does not establish that the medicine caused every reported case.

Sudden, painless vision loss or a new blind spot needs urgent medical assessment. People taking a prescribed medicine should discuss treatment decisions with their clinician rather than make changes based on a population-level risk estimate.

Common gastrointestinal effects

Nausea, diarrhoea, vomiting, constipation, abdominal pain and indigestion are among the most common adverse effects. Reduced appetite is also common in weight-management studies.

These reactions are often more noticeable while exposure is changing, but they can be persistent or severe. Approved treatment uses a gradual schedule partly to reduce gastrointestinal effects. This guide does not reproduce that schedule or provide dose advice.

Ongoing vomiting or diarrhoea can cause dehydration. Severe or persistent symptoms should not be treated as an expected inconvenience without clinical assessment.

Severe gastrointestinal reactions and gastroparesis

Tirzepatide delays stomach emptying and can cause severe gastrointestinal reactions. Current labels state that Mounjaro and Zepbound are not recommended in people with severe gastroparesis, a condition in which the stomach empties abnormally slowly.

Delayed stomach emptying is part of the medicine's pharmacology. That does not mean every person develops gastroparesis, but severe or persistent digestive symptoms need medical review.

Pancreatitis

Acute pancreatitis has been observed with GLP-1 receptor agonists and tirzepatide. Pancreatitis is inflammation of the pancreas and can be serious. Current labels advise stopping the medicine if pancreatitis is suspected and assessing the patient clinically.

A general guide cannot diagnose pancreatitis. Severe or persistent abdominal pain, especially with vomiting or pain moving towards the back, needs urgent medical advice.

Gallbladder disease

Gallstones and inflammation of the gallbladder have occurred in tirzepatide clinical programmes. Weight loss itself can also increase gallstone risk, particularly when it is rapid.

Symptoms suggesting gallbladder disease need medical assessment rather than being assumed to be an ordinary stomach side effect.

Kidney injury linked to dehydration

Acute kidney injury has been reported, often after gastrointestinal reactions caused substantial fluid loss. People with existing kidney problems may have less reserve, but dehydration can affect kidney function even without known kidney disease.

This warning does not cancel the favourable kidney signals in some trials. A medicine can improve longer-term disease markers in a defined population and still cause acute harm when an adverse effect leads to dehydration.

Low blood glucose

Tirzepatide's insulin-releasing effect is glucose-dependent, so low blood glucose is less common when it is used without insulin or an insulin-releasing medicine. The risk rises when these treatments are combined.

Diabetes treatment changes need a prescriber who can review the complete medicine list and glucose readings. Trial combinations are not instructions for self-directed treatment.

Diabetic retinopathy

Rapid improvement in blood glucose can temporarily worsen diabetic retinopathy in some people. Current labels advise monitoring people with a history of diabetic retinopathy and seeking assessment if vision changes occur.

This risk belongs mainly to the diabetes context. It should not be shortened to a claim that tirzepatide damages everyone's eyes.

Allergic reactions

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. The approved products are contraindicated in people who have previously had a serious hypersensitivity reaction to tirzepatide or the relevant product ingredients.

Inactive ingredients and product presentations matter. A reaction to a finished medicine needs clinical assessment rather than an assumption about the peptide alone.

Oral medicines and hormonal contraception

Because tirzepatide delays stomach emptying, it can affect how quickly some oral medicines are absorbed. The current labels also warn that oral hormonal contraceptives may be less effective during parts of treatment.

Anyone relying on an oral hormonal contraceptive should discuss the current label advice with a prescriber or pharmacist. This page does not provide a contraception timetable or replace individual advice.

Anaesthesia and deep sedation

Delayed stomach emptying can leave stomach contents present before a procedure. Rare cases of pulmonary aspiration have been reported during general anaesthesia or deep sedation. Pulmonary aspiration means stomach contents enter the lungs.

Current labels tell patients to inform healthcare professionals about tirzepatide before planned procedures. Decisions about pausing a medicine depend on the procedure, symptoms and individual risk. This guide does not provide a stopping schedule.

Pregnancy

Weight loss offers no benefit during pregnancy and may cause fetal harm. The Zepbound label advises stopping the medicine when pregnancy is recognised. The Mounjaro label also describes potential fetal risk based on animal data and the need to balance diabetes treatment against the risks of poorly controlled blood glucose.

Pregnancy planning, contraception and diabetes control need individual medical care. A general guide cannot turn label warnings into a personal treatment plan.

BOXED WARNING

What does the boxed thyroid warning mean?

Mounjaro and Zepbound carry a boxed warning about thyroid C-cell tumours. A boxed warning is the FDA's most prominent warning format.

Tirzepatide caused thyroid C-cell tumours in rats at clinically relevant exposures. It is not known whether tirzepatide causes these tumours, including medullary thyroid carcinoma, in humans.

The animal finding is not proof that tirzepatide causes thyroid cancer in people. It also cannot be dismissed as irrelevant. The human risk remains unknown, and that uncertainty shapes the contraindications and patient counselling in the approved labels.

The products must not be used by people with a personal or family history of medullary thyroid carcinoma or by people with multiple endocrine neoplasia syndrome type 2. The labels state that routine calcitonin testing or thyroid ultrasound is of uncertain value for early detection in people using tirzepatide.

CONTRAINDICATIONS

Who should not use tirzepatide?

A general guide cannot decide whether tirzepatide is suitable for a particular person. The current Mounjaro and Zepbound labels list two core contraindications:

  • A personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2
  • A previous serious hypersensitivity reaction to tirzepatide or ingredients in the relevant product

Other warnings and precautions affect people with severe digestive disease, pancreatitis symptoms, gallbladder disease, kidney risk, diabetic retinopathy, pregnancy or planned procedures. Other diabetes medicines can change the risk of low blood glucose.

Contraindication means the product should not be used in that situation. Warning or precaution means the prescriber needs to assess and manage the risk. Neither category is a checklist for self-prescribing.

Zepbound should not be used with another tirzepatide-containing product, and its label does not recommend use with another GLP-1 receptor agonist. This guide does not provide combination or switching instructions.

APPROVAL SCOPE

Approved tirzepatide is not the same as every tirzepatide product

An approved tirzepatide medicine is a complete product. The active ingredient, formulation, manufacturing process, product presentation, purity, stability, labelling and clinical evidence have been reviewed for specific uses.

A vial, powder or product page using the word tirzepatide has not automatically passed that review. It should not be described as Mounjaro, Zepbound, a generic version or clinically equivalent unless the regulator has approved it on that basis.

Compounded tirzepatide

Compounding can have a legitimate role when an individual patient's clinical need cannot be met by an available approved medicine and legal requirements are satisfied. Compounded drugs are not FDA-approved. The FDA does not review their safety, effectiveness or quality before marketing.

The FDA has warned about fraudulent products labelled as compounded tirzepatide, including labels naming pharmacies that did not make the product. It has also taken action against marketing that calls compounded GLP-1 products generic, the same as approved brands or clinically proven from the approved products' trials.

Evidence for Mounjaro and Zepbound cannot establish the formulation, concentration, sterility, stability or performance of a compounded preparation.

Research-labelled tirzepatide

Material labelled for research use only is not an approved medicine. The label does not establish pharmaceutical identity, purity, sterility, concentration, stability or suitability for use in people or animals.

A research vial also lacks the reviewed product presentation and patient information of an approved medicine. This guide does not provide buying, mixing, measuring or administration guidance for research material.

Does shortage status make compounded tirzepatide approved?

No. Shortage policy can affect when certain pharmacies or outsourcing facilities may compound copies of an approved drug under US law. It does not turn the compounded product into an FDA-approved medicine.

The FDA determined that the national tirzepatide injection shortage was resolved and later clarified its enforcement position for compounders. Shortage and enforcement information can change, so the current FDA position should be checked directly rather than copied from an old product page.

SourcesFDA, 2026
COMPARISON

Tirzepatide compared with semaglutide

Tirzepatide and semaglutide are both modified peptide medicines, but they are different molecules and do not activate exactly the same receptor system.

FeatureTirzepatideSemaglutide
Main receptor activityGIP and GLP-1 receptor agonistGLP-1 receptor agonist
Peptide backbone39 amino acids, based mainly on GIP31 amino acids, based on GLP-1
Approved brand examplesMounjaro and ZepboundOzempic, Wegovy and Rybelsus
Approved oral productNoYes
Are they interchangeable?NoNo

SURPASS-2 directly compared tirzepatide with injectable semaglutide in adults with type 2 diabetes taking metformin. Tirzepatide produced larger average reductions in HbA1c and body weight at the studied treatment levels.

The result belongs to that trial. It does not compare every approved product, every semaglutide treatment level, cardiovascular outcomes, kidney outcomes, safety for a particular person or long-term results across all conditions.

Semaglutide has a longer development history, approved oral formulations and dedicated placebo-controlled outcomes evidence across several conditions. Tirzepatide has its own strong diabetes and weight-management evidence, a dual-receptor mechanism, a current sleep-apnoea indication and newer trials in cardiovascular disease, heart failure and MASH.

The useful question is not which molecule is universally better. It is which product has evidence and approval for the outcome and person being considered.

For the full companion guide, read What Is Semaglutide?.

OPEN QUESTIONS

What do we still not know?

Very long-term treatment

Diabetes and weight-management trials now cover several years, and SURPASS-CVOT followed participants for about four years. This is enough to answer important questions, but it is not lifetime evidence. Longer observation will improve estimates of durability and rare adverse events.

Results after longer periods without treatment

SURMOUNT-4 showed average weight regain after withdrawal. Less is known about outcomes after many years of treatment, which people maintain more of the change and which forms of continued support help after stopping.

How much benefit comes from each receptor

Tirzepatide activates GIP and GLP-1 receptors, but researchers are still working out how much of each clinical effect comes from GIP activity, GLP-1 activity, altered signalling at the receptors or the resulting weight and metabolic changes.

Heart failure, MASH and kidney disease

Trials have produced encouraging findings, but questions remain about which patients benefit most, how durable the effects are and whether findings translate into the clinical outcomes required for broader approval. MASH evidence needs larger and longer trials, while kidney evidence needs more dedicated outcomes testing.

Cardiovascular benefit against placebo

SURPASS-CVOT compared tirzepatide with dulaglutide and established noninferiority. It did not answer exactly the same question as a placebo-controlled cardiovascular trial and did not establish superiority for the primary outcome.

Rare harms and broader populations

Clinical trials cannot measure every rare event precisely. Post-marketing surveillance remains important. Evidence also remains narrower for pregnancy, some age groups, people with severe digestive disease and those with complex combinations of conditions.

COMMON QUESTIONS

Frequently asked questions

Is tirzepatide a peptide or a protein?

Tirzepatide is described as a peptide. It has a defined chain of 39 amino-acid residues and several chemical modifications. Protein is generally used for larger or more structurally complex amino-acid molecules, although the boundary between the terms is not absolute.

Is tirzepatide natural or synthetic?

Tirzepatide is synthetic. Its design is based mainly on the natural human hormone GIP, but the sequence and side chain were deliberately modified. It is manufactured rather than extracted from the human body.

How many amino acids are in tirzepatide?

Tirzepatide has a 39-amino-acid peptide backbone. Two positions contain the non-coded amino acid Aib, and a fatty diacid side chain is attached through a linker at another position.

Is tirzepatide a GLP-1 medicine?

Tirzepatide activates the GLP-1 receptor, but it also activates the GIP receptor. GLP-1 medicine is common shorthand. The more complete description is a dual GIP and GLP-1 receptor agonist.

Is tirzepatide the same as Mounjaro?

Tirzepatide is the active ingredient in Mounjaro. Mounjaro is the complete approved medicine, including its formulation, manufacturing controls, product presentation, label and approved use.

Is tirzepatide the same as Zepbound?

Tirzepatide is the active ingredient in Zepbound. Zepbound is an approved finished medicine with weight-management and obstructive sleep apnoea indications for defined adult groups.

Is Mounjaro approved for weight loss?

Mounjaro has US indications for type 2 diabetes and cardiovascular risk reduction in defined adults with type 2 diabetes. It does not have a general weight-management indication. Zepbound is the tirzepatide product with the defined weight-management indication. Results or uses should not be moved from one brand label to another.

Is tirzepatide approved for obstructive sleep apnoea?

Zepbound is approved in the United States to treat moderate to severe obstructive sleep apnoea in adults with obesity. This is a product-specific indication and does not mean tirzepatide treats every form of sleep apnoea.

Is tirzepatide the same as semaglutide?

No. They are different peptide molecules. Tirzepatide activates GIP and GLP-1 receptors, while semaglutide activates the GLP-1 receptor. They are active ingredients in different approved medicines.

Is Wegovy tirzepatide?

No. Wegovy contains semaglutide. Mounjaro and Zepbound contain tirzepatide.

Is tirzepatide insulin?

No. Tirzepatide is a dual incretin-receptor agonist. It can increase insulin release when blood glucose is elevated, but it is not insulin and does not replace insulin in every person who needs it.

Is tirzepatide a steroid?

No. Tirzepatide is an amino-acid peptide. Steroids have a different ring-based chemical structure and act through different receptor systems.

What happens when tirzepatide is stopped?

In the SURMOUNT-4 withdrawal trial, participants who changed from tirzepatide to placebo regained weight on average, while those who continued treatment lost more. This does not predict one person’s outcome, but it shows that results during treatment should not be assumed to be permanent after treatment ends.

Does tirzepatide prevent heart attacks or strokes?

SURPASS-CVOT found tirzepatide noninferior to dulaglutide for major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. It did not establish superiority for the primary outcome. The current Mounjaro label includes reducing major cardiovascular events in adults with type 2 diabetes who are at high risk; this does not cover every person with obesity.

Is tirzepatide approved for MASH or heart failure?

No current US Mounjaro or Zepbound indication covers MASH or heart failure. Human trials have produced promising results in both areas, but research evidence and regulatory approval are not the same thing.

Is compounded or research tirzepatide the same as Mounjaro or Zepbound?

No assumption of equivalence should be made. Compounded drugs are not FDA-approved, and research-labelled material is not an approved medicine. Neither automatically has the formulation, manufacturing controls, device, stability evidence or clinical support of Mounjaro or Zepbound.

THE BOTTOM LINE

Tirzepatide is a modified dual-receptor peptide medicine

Tirzepatide is a synthetic 39-amino-acid peptide based mainly on GIP. Structural changes help it resist rapid breakdown, bind to albumin and remain active much longer than natural incretin hormones.

The molecule activates GIP and GLP-1 receptors. Its effects include glucose-dependent insulin release, lower glucagon, delayed stomach emptying and changes in appetite and food intake.

Tirzepatide is the active ingredient in Mounjaro and Zepbound. Mounjaro has type 2 diabetes and defined cardiovascular-risk-reduction indications. Zepbound has weight-management and obstructive sleep apnoea indications for defined adults. Research in cardiovascular disease, heart failure, kidney outcomes and MASH adds useful evidence without automatically expanding those approved uses.

The evidence base is extensive, but the medicine has important contraindications, gastrointestinal effects, serious warnings and an unresolved human question behind its boxed thyroid warning. Approved products should not be treated as equivalent to compounded or research-labelled material carrying the same ingredient name.

OUR RESEARCH STANDARD

See how Orentra reviews peptide research

Human, animal and laboratory findings are not treated as equivalent evidence. See how we select sources, assess studies, apply evidence labels and keep guides up to date.

Read our research methodology →
RESEARCH AND MEDICAL NOTICE

Research and medical notice

This guide is for educational purposes. It does not provide medical advice, diagnosis, prescribing guidance, dosage information, injection instructions, reconstitution steps or purchasing advice.

Tirzepatide is an active prescription medicine with important contraindications, warnings and interactions. Questions about personal suitability, treatment changes or side effects belong with a qualified healthcare professional.

Orentra's catalogue is an educational research resource. A catalogue entry does not imply that an unapproved, compounded or research-labelled product is equivalent to Mounjaro, Zepbound or another approved medicine.

RELATED READING

Keep exploring the peptide knowledge base

Read the semaglutide companion guide, start with peptide fundamentals or return to the catalogue to browse other research guides.

RESEARCH LIBRARY

Sources

Current DailyMed prescribing information is the primary source for approved uses, pharmacology, contraindications and safety warnings. FDA materials and primary human studies provide the regulatory and clinical evidence.

Prescribing informationDailyMedCurrent
DailyMed: Mounjaro, tirzepatide injection, current US prescribing information

Current US prescribing information for Mounjaro, including its approved use, pharmacology, contraindications, warnings and clinical studies.

Open source →
Prescribing informationDailyMedCurrent
DailyMed: Zepbound, tirzepatide injection, current US prescribing information

Current US prescribing information for Zepbound, including weight-management and obstructive sleep apnoea uses, contraindications and safety information.

Open source →
Regulatory announcementFDA2023
FDA: Approval of Zepbound for chronic weight management

FDA announcement describing the original Zepbound weight-management approval and the evidence used to support it.

Open source →
Regulatory announcementFDA2024
FDA: Approval of Zepbound for obstructive sleep apnoea

FDA announcement of the Zepbound indication for moderate to severe obstructive sleep apnoea in adults with obesity.

Open source →
Safety informationFDA2026
FDA: Concerns with unapproved GLP-1 drugs used for weight loss

Current FDA information about unapproved and fraudulent products marketed using semaglutide or tirzepatide names.

Open source →
Regulatory updateFDA2026
FDA: Tirzepatide shortage and compounding policy update

FDA information about the resolved national tirzepatide shortage and the resulting position for compounders.

Open source →
Regulatory updateFDA2026
FDA: Action against misleading claims for non-approved compounded GLP-1 drugs

FDA statement explaining that compounded products cannot be marketed as generic, clinically equivalent or the same as approved GLP-1 medicines.

Open source →
Development researchMolecular Metabolism2018
Coskun et al.: LY3298176, a novel dual GIP and GLP-1 receptor agonist

Original development research describing the fatty-acid-modified peptide later named tirzepatide and its receptor activity.

Open source →
Mechanistic researchJCI Insight2020
Willard et al.: Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Laboratory research examining how tirzepatide activates and signals through the GIP and GLP-1 receptors.

Open source →
Structural researchNature Communications2022
Sun et al.: Structural determinants of dual incretin receptor agonism by tirzepatide

Structural research showing how tirzepatide interacts with the GIP and GLP-1 receptors.

Open source →
Phase 2 human trialThe Lancet2018
Frías et al.: Early human trial of LY3298176 in type 2 diabetes

Randomised phase 2 trial of the development compound LY3298176, which was later named tirzepatide.

Open source →
Diabetes trialThe Lancet2021
Rosenstock et al.: Tirzepatide monotherapy in type 2 diabetes, SURPASS-1

Randomised placebo-controlled trial of tirzepatide in adults with type 2 diabetes managed without other glucose-lowering medicines at enrolment.

Open source →
Head-to-head diabetes trialNew England Journal of Medicine2021
Frías et al.: Tirzepatide compared with semaglutide in type 2 diabetes, SURPASS-2

Randomised trial directly comparing tirzepatide with injectable semaglutide in adults with type 2 diabetes.

Open source →
Diabetes trialThe Lancet2021
Ludvik et al.: Tirzepatide compared with insulin degludec, SURPASS-3

Randomised trial comparing tirzepatide with titrated insulin degludec in adults with type 2 diabetes.

Open source →
Diabetes trialThe Lancet2021
Del Prato et al.: Tirzepatide compared with insulin glargine in higher-risk type 2 diabetes, SURPASS-4

Randomised trial in adults with type 2 diabetes and increased cardiovascular risk.

Open source →
Diabetes trialJAMA2022
Dahl et al.: Tirzepatide added to insulin glargine, SURPASS-5

Randomised placebo-controlled trial in adults whose type 2 diabetes was not adequately controlled with insulin glargine.

Open source →
Cardiovascular outcomes trialNew England Journal of Medicine2025
Nicholls et al.: Cardiovascular outcomes with tirzepatide compared with dulaglutide, SURPASS-CVOT

Large cardiovascular outcomes trial in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.

Open source →
Weight-management trialNew England Journal of Medicine2022
Jastreboff et al.: Tirzepatide for obesity treatment, SURMOUNT-1

Large randomised trial of tirzepatide and lifestyle intervention in adults with obesity or overweight without diabetes.

Open source →
Weight-management trialThe Lancet2023
Garvey et al.: Tirzepatide for obesity in people with type 2 diabetes, SURMOUNT-2

Randomised trial studying weight management in adults who had both excess weight and type 2 diabetes.

Open source →
Weight-management trialNature Medicine2023
Wadden et al.: Tirzepatide after intensive lifestyle intervention, SURMOUNT-3

Randomised trial studying tirzepatide after participants had first completed an intensive lifestyle programme.

Open source →
Withdrawal trialJAMA2024
Aronne et al.: Continued tirzepatide treatment for maintenance of weight reduction, SURMOUNT-4

Randomised withdrawal trial comparing continued treatment with a change to placebo after an initial tirzepatide period.

Open source →
Long-term human trialNew England Journal of Medicine2025
Jastreboff et al.: Tirzepatide for obesity treatment and diabetes prevention

Three-year findings in participants with obesity and prediabetes from the SURMOUNT-1 programme.

Open source →
Sleep apnoea trialNew England Journal of Medicine2024
Malhotra et al.: Tirzepatide for obstructive sleep apnoea and obesity, SURMOUNT-OSA

Two randomised trials in adults with moderate to severe obstructive sleep apnoea and obesity, with and without positive airway pressure use.

Open source →
Heart-failure trialNew England Journal of Medicine2025
Packer et al.: Tirzepatide for heart failure with preserved ejection fraction and obesity, SUMMIT

Randomised trial evaluating heart-failure events and health status in people with preserved ejection fraction and obesity.

Open source →
Kidney analysisThe Lancet Diabetes & Endocrinology2022
Heerspink et al.: Kidney outcomes with tirzepatide in SURPASS-4

Post hoc analysis of estimated kidney function, urine albumin and a composite kidney outcome in SURPASS-4.

Open source →
Liver trialNew England Journal of Medicine2024
Loomba et al.: Tirzepatide for MASH with liver fibrosis, SYNERGY-NASH

Phase 2 trial in adults with biopsy-confirmed MASH and moderate or severe fibrosis.

Open source →
Regulatory safety communicationUS FDA2026
FDA: GLP-1 receptor agonists and potential risk of NAION, 9 November 2026

Class-wide safety labelling action following a review of randomised trials and other evidence.

Open source →
Phase 3 human randomised trialJAMA2026
Kelly and colleagues: SURMOUNT-ADOLESCENTS, published 15 November 2026

Randomised study of tirzepatide versus placebo in 160 adolescents, with 72-week BMI and safety outcomes.

Open source →

Last reviewed: 17 November 2026.